Prolonged QTc Interval
8
0
0
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
12.5%
1 terminated out of 8 trials
87.5%
+1.0% vs benchmark
38%
3 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (8)
Smoking and Ventricular Repolarization
Effect of Estetrol Monohydrate (E4) on QTc Interval
Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects
Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women
Ramosetron Pre-treatment for PONV and QT Prolongation
Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation
Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects
Granisetron Versus Ondansetron: Comparative Effects on ECG, QTc